Investors Target Beta Bionics Over Alleged Insulin Pump Failures

The litigation centers on the company’s flagship automated insulin delivery system, the iLet. Throughout the class period, executives downplayed concerns raised by the FDA in October 2025, characterizing them as minor administrative issues regarding the reporting of customer complaints. Investors were told the company was rectifying its data interpretation and that the device itself remained safe and effective.

However, a February 2026 public disclosure of a formal FDA warning letter revealed a different reality. The document outlined systemic failures, including reports of the device malfunctioning and delivering excessive insulin doses that led to life-threatening hypoglycemic events. This revelation caused shares to plummet from $31.99 on January 9, 2026, to $12.89 by February 25, 2026.

Robbins LLP is currently seeking investors who suffered losses during this period to serve as lead plaintiff. The firm notes that those interested in participating must contact them before the November 3, 2026, deadline. Legal representation in this matter is handled on a contingency basis, meaning no upfront costs are required for shareholders to join the class.